Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials
Advances in Therapy · 2025
DOI: 10.1007/s12325-024-03095-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Khashayar Azimpour und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chiesi, 3800 Steeles Ave. West, Suite 100E, Woodbridge, ON, L4L 4G9, Canada. k.azimpour@chiesi.com. Hauptthemen laut MEDLINE: alpha-Galactosidase, Enzyme Replacement Therapy, Fabry Disease, Quality of Life. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chiesi USA.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chiesi, 3800 Steeles Ave. West, Suite 100E, Woodbridge, ON, L4L 4G9, Canada. k.azimpour@chiesi.com.
- Chiesi, Boston, MA, USA.
- Cytel, Inc., Waltham, MA, USA.
ORCID-Profile: Khashayar Azimpour
Förderung
- Chiesi USA
Zitieren
APA
Azimpour, K., Dorling, P., Koulinska, I., Kunduri, S., Lan, Z., Poritz, J., Tremblay, G., & Raad-Faherty, A. (2025). Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials. Advances in Therapy. https://doi.org/10.1007/s12325-024-03095-2
Vancouver
Azimpour K, Dorling P, Koulinska I, Kunduri S, Lan Z, Poritz J, et al. Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials. Advances in Therapy. 2025. doi:10.1007/s12325-024-03095-2
BibTeX
@article{Azimpour2025,
author = {Azimpour, Khashayar and Dorling, Patricia and Koulinska, Irene and Kunduri, Swati and Lan, Zhiyi and Poritz, Julia and Tremblay, Gabriel and Raad-Faherty, Angie},
title = {Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-024-03095-2}
}
EUVIMED